Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 131 articles:
HTML format
Text format



Single Articles


    August 2017
  1. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Text format     Abstract available


  2. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Text format     Abstract available


  3. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Text format     Abstract available


  4. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Text format     Abstract available


  5. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Text format     Abstract available


  6. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Text format     Abstract available


    June 2017
  7. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Text format     Abstract available


  8. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Text format     Abstract available


  9. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Text format     Abstract available


  10. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Text format     Abstract available


  11. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Text format     Abstract available


  12. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Text format     Abstract available


    May 2017
  13. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Text format     Abstract available


  14. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Text format     Abstract available


  15. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Text format     Abstract available


  16. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Text format     Abstract available


  17. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Text format     Abstract available


    April 2017
  18. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Text format     Abstract available


  19. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Text format     Abstract available


  20. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Text format     Abstract available


  21. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Text format     Abstract available


    February 2017
  22. DEPAULA-SILVA AB, Hanak TJ, Libbey JE, Fujinami RS, et al
    Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.
    J Neuroimmunol. 2017 Feb 12. pii: S0165-5728(16)30480.
    PubMed     Text format     Abstract available


    December 2016
  23. ANNUNZIATA P, Cioni C, Mugnaini C, Corelli F, et al
    Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
    J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274.
    PubMed     Text format     Abstract available


  24. PAOLICELLI D, Manni A, D'Onghia M, Direnzo V, et al
    Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    J Neuroimmunol. 2016 Dec 21. pii: S0165-5728(16)30371.
    PubMed     Text format     Abstract available


  25. MATUTE-BLANCH C, Rio J, Villar LM, Midaglia L, et al
    Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 18. pii: S0165-5728(16)30310.
    PubMed     Text format     Abstract available


  26. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Text format     Abstract available


  27. GORDON-LIPKIN E, Calabresi PA
    Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 14. pii: S0165-5728(16)30447.
    PubMed     Text format     Abstract available


  28. HOSSAIN MJ, Tanasescu R, Gran B
    Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.
    J Neuroimmunol. 2016 Dec 13. pii: S0165-5728(16)30448.
    PubMed     Text format     Abstract available


    November 2016
  29. HAGHMORAD D, Mahmoudi MB, Salehipour Z, Jalayer Z, et al
    Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 26. pii: S0165-5728(16)30423.
    PubMed     Text format     Abstract available


  30. PROKOPOVA B, Hlavacova N, Vlcek M, Penesova A, et al
    Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis.
    J Neuroimmunol. 2016 Nov 19. pii: S0165-5728(16)30241.
    PubMed     Text format     Abstract available


  31. ACHIRON A, Zilkha-Falb R, Mashiach R, Gurevich M, et al
    RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30209.
    PubMed     Text format     Abstract available


  32. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Angiogenic factors are associated with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30304.
    PubMed     Text format     Abstract available


  33. ZHANG Y, Liu G, Duan Y, Han X, et al
    Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China.
    J Neuroimmunol. 2016 Nov 16. pii: S0165-5728(16)30187.
    PubMed     Text format     Abstract available


  34. MURIS AH, Smolders J, Rolf L, Thewissen M, et al
    Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study.
    J Neuroimmunol. 2016;300:47-56.
    PubMed     Text format     Abstract available


  35. DIAS-CARNEIRO RP, von Glehn F, Moraes AS, Boldrini VO, et al
    MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.
    J Neuroimmunol. 2016;300:30-35.
    PubMed     Text format     Abstract available


  36. KALINOWSKA-LYSZCZARZ A, Michalak S, Pawlak MA, Losy J, et al
    Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis.
    J Neuroimmunol. 2016;300:11-14.
    PubMed     Text format     Abstract available


  37. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Text format     Abstract available


  38. HAAS J, Schwarz A, Korporal-Kuhnke M, Jarius S, et al
    Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 2. pii: S0165-5728(16)30258.
    PubMed     Text format     Abstract available


  39. AHARONI R, Rosen C, Shezen E, Bar-Lev DD, et al
    Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 1. pii: S0165-5728(16)30381.
    PubMed     Text format     Abstract available


    October 2016
  40. MELIEF J, Koper JW, Endert E, Moller HJ, et al
    Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
    J Neuroimmunol. 2016;299:84-89.
    PubMed     Text format     Abstract available


  41. FENOGLIO C, De Riz M, Pietroboni AM, Calvi A, et al
    Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    J Neuroimmunol. 2016;299:81-83.
    PubMed     Text format     Abstract available


  42. DA COSTA DS, Hygino J, Ferreira TB, Kasahara TM, et al
    Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:8-18.
    PubMed     Text format     Abstract available


  43. BRIKEN S, Rosenkranz SC, Keminer O, Patra S, et al
    Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2016;299:53-58.
    PubMed     Text format     Abstract available


  44. JONS D, Kneider M, Fogelstrand L, Jeppsson A, et al
    Early hematopoiesis in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:158-163.
    PubMed     Text format     Abstract available


  45. DOOLEY MM, de Gannes SL, Fu KA, Lindsey JW, et al
    The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
    J Neuroimmunol. 2016;299:147-151.
    PubMed     Text format     Abstract available


  46. WALLER R, Woodroofe MN, Wharton SB, Ince PG, et al
    Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
    J Neuroimmunol. 2016;299:139-146.
    PubMed     Text format     Abstract available


  47. MANE-MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    J Neuroimmunol. 2016;299:112-117.
    PubMed     Text format     Abstract available


  48. CROSS AH, Song SK
    "A new imaging modality to non-invasively assess multiple sclerosis pathology".
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30328.
    PubMed     Text format     Abstract available


  49. REICH DS
    Imag(in)ing multiple sclerosis: Time to take better pictures.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30307.
    PubMed     Text format     Abstract available


  50. ITOH N, Kim R, Peng M, DiFilippo E, et al
    Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30308.
    PubMed     Text format     Abstract available


    September 2016
  51. BOIOCCHI C, Monti MC, Osera C, Mallucci G, et al
    Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis.
    J Neuroimmunol. 2016;298:189-93.
    PubMed     Text format     Abstract available


  52. TAO Y, Zhang X, Markovic-Plese S
    Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    J Neuroimmunol. 2016;298:181-8.
    PubMed     Text format     Abstract available


  53. OZGUN-ACAR O, Celik-Turgut G, Gazioglu I, Kolak U, et al
    Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice.
    J Neuroimmunol. 2016;298:106-16.
    PubMed     Text format     Abstract available


  54. COSENTINO M, Zaffaroni M, Legnaro M, Bombelli R, et al
    Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
    J Neuroimmunol. 2016;298:82-9.
    PubMed     Text format     Abstract available


  55. MIYAZAKI Y, Niino M, Kanazawa I, Suzuki M, et al
    Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
    J Neuroimmunol. 2016;298:24-31.
    PubMed     Text format     Abstract available


  56. EFTHYMIOU G, Dardiotis E, Liaskos C, Marou E, et al
    Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.
    J Neuroimmunol. 2016;298:19-23.
    PubMed     Text format     Abstract available


  57. TANAKA M, Tanaka K
    Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;298:16-8.
    PubMed     Text format     Abstract available


    August 2016
  58. ZHANG Y, Liu G, Han X, Dong H, et al
    The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
    J Neuroimmunol. 2016;297:127-31.
    PubMed     Text format     Abstract available


  59. PUTHENPARAMPIL M, Miante S, Federle L, Zanetta C, et al
    BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset.
    J Neuroimmunol. 2016;297:63-7.
    PubMed     Text format     Abstract available


  60. CALA CM, Moseley CE, Steele C, Dowdy SM, et al
    T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.
    J Neuroimmunol. 2016;297:1-8.
    PubMed     Text format     Abstract available


  61. LOVETT-RACKE AE
    Contribution of EAE to understanding and treating multiple sclerosis.
    J Neuroimmunol. 2016 Aug 12. pii: S0165-5728(16)30195.
    PubMed     Text format     Abstract available


    July 2016
  62. LEVIN MC, Lee S, Gardner LA, Shin Y, et al
    Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30155.
    PubMed     Text format     Abstract available


  63. NIMMAGADDA VK, Makar TK, Chandrasekaran K, Sagi AR, et al
    SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30158.
    PubMed     Text format     Abstract available


  64. VALENZUELA RM, Kaufman M, Balashov KE, Ito K, et al
    Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    J Neuroimmunol. 2016 Jul 2. pii: S0165-5728(16)30137.
    PubMed     Text format     Abstract available


    June 2016
  65. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    Corrigendum to "An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility" [Journal of Neuroimmunology 290 (2016) 115-118].
    J Neuroimmunol. 2016;295-296:164.
    PubMed     Text format    


  66. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].
    J Neuroimmunol. 2016;295-296:163.
    PubMed     Text format    


  67. HUANG Q, Xiao B, Ma X, Qu M, et al
    MicroRNAs associated with the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2016;295-296:148-61.
    PubMed     Text format     Abstract available


  68. ANSARI QESHMI S, Dabbagh F, Borhani Haghighi A, Ghasemi Y, et al
    Bioinformatics evaluation of the possibility of heat shock proteins as autoantigens in multiple sclerosis based on molecular mimicry hypothesis.
    J Neuroimmunol. 2016;295-296:100-21.
    PubMed     Text format     Abstract available


    May 2016
  69. RAINE CS
    Multiple sclerosis: The resolving lesion revealed.
    J Neuroimmunol. 2016 May 27. pii: S0165-5728(16)30129.
    PubMed     Text format     Abstract available


  70. CATANZARO G, Pucci M, Viscomi MT, Lanuti M, et al
    Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016;294:32-40.
    PubMed     Text format     Abstract available


  71. HAAS J, Schwarz A, Korporal-Kuhnke M, Faller S, et al
    Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
    J Neuroimmunol. 2016;294:18-26.
    PubMed     Text format     Abstract available


  72. ERDUR H, Scholz V, Streitz M, Hammer M, et al
    EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
    J Neuroimmunol. 2016;294:14-7.
    PubMed     Text format     Abstract available


  73. RIZZO R, Bortolotti D, Fainardi E, Gentili V, et al
    KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
    J Neuroimmunol. 2016;294:1-5.
    PubMed     Text format     Abstract available


    April 2016
  74. ALVARENGA-FILHO H, Sacramento PM, Ferreira TB, Hygino J, et al
    Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators.
    J Neuroimmunol. 2016;293:91-9.
    PubMed     Text format     Abstract available


  75. YAMOUT B, Karaky NM, Mahfouz RA, Jaber F, et al
    Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.
    J Neuroimmunol. 2016;293:59-64.
    PubMed     Text format     Abstract available


    March 2016
  76. MELNIKOV M, Belousova O, Murugin V, Pashenkov capital EM, Cyrillic, et al
    The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.
    J Neuroimmunol. 2016;292:97-101.
    PubMed     Text format     Abstract available


  77. SMOLDERS J, Muris AH, Damoiseaux J
    Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.
    J Neuroimmunol. 2016;292:79-80.
    PubMed     Text format    


  78. MAGNER WJ, Weinstock-Guttman B, Rho M, Hojnacki D, et al
    Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
    J Neuroimmunol. 2016;292:68-78.
    PubMed     Text format     Abstract available


  79. BURMAN J, Raininko R, Blennow K, Zetterberg H, et al
    YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:52-7.
    PubMed     Text format     Abstract available


  80. BURMAN J, Svenningsson A
    Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:40-4.
    PubMed     Text format     Abstract available


  81. MARTIRE S, Navone ND, Montarolo F, Perga S, et al
    A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
    J Neuroimmunol. 2016;292:34-9.
    PubMed     Text format     Abstract available


  82. MAKAR TK, Nimmagadda VK, Singh IS, Lam K, et al
    TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis.
    J Neuroimmunol. 2016;292:9-20.
    PubMed     Text format     Abstract available


  83. MAUSNER-FAINBERG K, Kolb H, Penn M, Regev K, et al
    Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-beta.
    J Neuroimmunol. 2016;292:93-6.
    PubMed     Text format     Abstract available


    February 2016
  84. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
    J Neuroimmunol. 2016;291:73-7.
    PubMed     Text format     Abstract available


  85. FORWELL AL, Bernales CQ, Ross JP, Yee IM, et al
    Analysis of CH25H in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2016;291:70-2.
    PubMed     Text format     Abstract available


  86. IRELAND SJ, Guzman AA, Frohman EM, Monson NL, et al
    B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.
    J Neuroimmunol. 2016;291:46-53.
    PubMed     Text format     Abstract available


  87. MADEIRA A, Burgelin I, Perron H, Curtin F, et al
    MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
    J Neuroimmunol. 2016;291:29-38.
    PubMed     Text format     Abstract available


  88. ZAHEDNASAB H, Karampoor S
    The correlation of HLA-G with multiple sclerosis.
    J Neuroimmunol. 2016;291:28.
    PubMed     Text format    


  89. BLAIR TC, Manoharan M, Rawlings-Rhea SD, Tagge I, et al
    Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.
    J Neuroimmunol. 2016;291:1-10.
    PubMed     Text format     Abstract available


  90. MIYAJI K, Paul F, Shahrizaila N, Umapathi T, et al
    Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases.
    J Neuroimmunol. 2016;291:78-81.
    PubMed     Text format     Abstract available


    January 2016
  91. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility.
    J Neuroimmunol. 2016;290:115-8.
    PubMed     Text format     Abstract available


  92. KHORRAMDELAZAD H, Bagheri V, Hassanshahi G, Zeinali M, et al
    New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis.
    J Neuroimmunol. 2016;290:70-5.
    PubMed     Text format     Abstract available


  93. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Expression of DNA methylation genes in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;290:66-9.
    PubMed     Text format     Abstract available


  94. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study.
    J Neuroimmunol. 2016;290:47-8.
    PubMed     Text format     Abstract available


  95. HASSON T, Kolitz S, Towfic F, Laifenfeld D, et al
    Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    J Neuroimmunol. 2016;290:84-95.
    PubMed     Text format     Abstract available


  96. MAURER MA, Tuller F, Gredler V, Berger T, et al
    Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
    J Neuroimmunol. 2016;290:49-53.
    PubMed     Text format     Abstract available


    December 2015
  97. HORELLOU P, Wang M, Keo V, Chretien P, et al
    Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    J Neuroimmunol. 2015;289:1-7.
    PubMed     Text format     Abstract available


  98. MOHAJERI M, Sadeghizadeh M, Javan M
    Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
    J Neuroimmunol. 2015;289:105-10.
    PubMed     Text format     Abstract available


  99. YAMOUT BI, Zeineddine MM, Tamim H, Khoury SJ, et al
    Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
    J Neuroimmunol. 2015;289:93-7.
    PubMed     Text format     Abstract available


    November 2015
  100. KHOSRAVI A, Javan B, Tabatabaiefar MA, Ebadi H, et al
    Association of interleukin-1 gene cluster polymorphisms and haplotypes with multiple sclerosis in an Iranian population.
    J Neuroimmunol. 2015;288:114-9.
    PubMed     Text format     Abstract available


  101. NEGROTTO L, Canto E, Rio J, Tintore M, et al
    Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta.
    J Neuroimmunol. 2015;288:98-101.
    PubMed     Text format     Abstract available


  102. KVISTAD SS, Myhr KM, Holmoy T, Saltyte Benth J, et al
    Body mass index influence interferon-beta treatment response in multiple sclerosis.
    J Neuroimmunol. 2015;288:92-7.
    PubMed     Text format     Abstract available


  103. WAGNER M, Sobczynski M, Karabon L, Bilinska M, et al
    Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset.
    J Neuroimmunol. 2015;288:79-86.
    PubMed     Text format    


  104. LINSENBARDT HR, Cook JL, Young EE, Vichaya EG, et al
    Social disruption alters pain and cognition in an animal model of multiple sclerosis.
    J Neuroimmunol. 2015;288:56-68.
    PubMed     Text format     Abstract available


  105. TANAKA M, Kinoshita M
    Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
    J Neuroimmunol. 2015;288:69.
    PubMed     Text format     Abstract available


    October 2015
  106. EHLING R, Di Pauli F, Lackner P, Rainer C, et al
    Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
    J Neuroimmunol. 2015;287:98-105.
    PubMed     Text format     Abstract available


  107. MACCHI B, Marino-Merlo F, Nocentini U, Pisani V, et al
    Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system.
    J Neuroimmunol. 2015;287:80-7.
    PubMed     Text format     Abstract available


  108. DALLARI S, Franciotta D, Carluccio S, Signorini L, et al
    Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
    J Neuroimmunol. 2015;287:76-9.
    PubMed     Text format     Abstract available


  109. MILOSEVIC E, Dujmovic I, Markovic M, Mesaros S, et al
    Higher expression of IL-12Rbeta2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-beta1b therapy during 3-year follow-up.
    J Neuroimmunol. 2015;287:64-70.
    PubMed     Text format     Abstract available


  110. KEVIN LI-CHUN H, Schob S, Zeller MW, Pulli B, et al
    Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.
    J Neuroimmunol. 2015;287:36-42.
    PubMed     Text format     Abstract available


  111. BEPPU M, Sawai S, Satoh M, Mori M, et al
    Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2015;287:9-15.
    PubMed     Text format     Abstract available


    September 2015
  112. MAUSNER-FAINBERG K, Regev K, Kolb H, Vaknin-Dembinsky A, et al
    Increased neutralization capacity of TNF-alpha in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-alpha receptors or anti-TNF-alpha autoantibody levels.
    J Neuroimmunol. 2015;286:83-5.
    PubMed     Text format     Abstract available


  113. GASPAROVIC I, Cizmarevic NS, Lovrecic L, Perkovic O, et al
    MMP-2 -1575G/A polymorphism modifies the onset of optic neuritis as a first presenting symptom in MS?
    J Neuroimmunol. 2015;286:13-5.
    PubMed     Text format     Abstract available


    August 2015
  114. PFUHL C, Oechtering J, Rasche L, Giess RM, et al
    Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis.
    J Neuroimmunol. 2015;285:156-60.
    PubMed     Text format     Abstract available


  115. TOGHIANIFAR N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M, et al
    Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial.
    J Neuroimmunol. 2015;285:125-8.
    PubMed     Text format     Abstract available


  116. STASCHEIT F, Paul F, Harms L, Rosche B, et al
    Toxoplasma gondii seropositivity is negatively associated with multiple sclerosis.
    J Neuroimmunol. 2015;285:119-24.
    PubMed     Text format     Abstract available


  117. DERFUSS T, Curtin F, Guebelin C, Bridel C, et al
    A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
    J Neuroimmunol. 2015;285:68-70.
    PubMed     Text format     Abstract available


  118. AL-TEMAIMI R, Alroughani R, Jacob S, Al-Mulla F, et al
    Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait.
    J Neuroimmunol. 2015;285:57-61.
    PubMed     Text format     Abstract available


  119. YAMOUT BI, Zeineddine MM, Sawaya RA, Khoury SJ, et al
    Safety and efficacy of reduced fingolimod dosage treatment.
    J Neuroimmunol. 2015;285:13-5.
    PubMed     Text format     Abstract available


    July 2015
  120. MUTO M, Mori M, Hiwasa T, Takiguchi M, et al
    Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.
    J Neuroimmunol. 2015;284:30-6.
    PubMed     Text format     Abstract available


  121. TSONIS AI, Zisimopoulou P, Lazaridis K, Tzartos J, et al
    MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study.
    J Neuroimmunol. 2015;284:10-7.
    PubMed     Text format     Abstract available


    June 2015
  122. AKAISHI T, Nakashima I, Misu T, Fujihara K, et al
    Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2015;283:70-3.
    PubMed     Text format     Abstract available


  123. FERRARO D, Galli V, Vitetta F, Simone AM, et al
    Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis.
    J Neuroimmunol. 2015;283:64-9.
    PubMed     Text format     Abstract available


  124. PASQUALI L, Pecori C, Chico L, Iudice A, et al
    Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in Multiple Sclerosis patients.
    J Neuroimmunol. 2015;283:39-42.
    PubMed     Text format     Abstract available


  125. ZILKHA-FALB R, Gurevich M, Hayardeny L, Achiron A, et al
    The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
    J Neuroimmunol. 2015;283:11-6.
    PubMed     Text format     Abstract available


    May 2015
  126. VISWANATHAN S, Wong AH, Quek AM, Yuki N, et al
    Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    J Neuroimmunol. 2015;282:92-6.
    PubMed     Text format     Abstract available


  127. QUAN C, ZhangBao J, Lu J, Zhao C, et al
    The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
    J Neuroimmunol. 2015;282:45-53.
    PubMed     Text format     Abstract available


    April 2015
  128. LI H, Dai Y, Wu AM, Sun X, et al
    Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2015;281:38-43.
    PubMed     Text format     Abstract available


    March 2015
  129. PEELEN E, Muris AH, Damoiseaux J, Knippenberg S, et al
    GM-CSF production by CD4(+) T cells in MS patients: Regulation by regulatory T cells and vitamin D.
    J Neuroimmunol. 2015;280:36-42.
    PubMed     Text format     Abstract available


  130. SUN Y, Chen H, Dai J, Zou H, et al
    HMGB1 expression patterns during the progression of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2015;280:29-35.
    PubMed     Text format     Abstract available


  131. AIVO J, Hanninen A, Ilonen J, Soilu-Hanninen M, et al
    Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.
    J Neuroimmunol. 2015;280:12-5.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: